University of Surrey

Test tubes in the lab Research in the ATI Dance Research

The Phosphoinositide 3-Kinase/Akt Pathway: A New Target in Human Renal Cell Carcinoma Therapy

Sourbier, C, Lindner, V, Lang, H, Agouni, Abdelali, Schordan, E, Danilin, S, Rothhut, S, Jacqmin, D, Helwig, JJ and Massfelder, T (2006) The Phosphoinositide 3-Kinase/Akt Pathway: A New Target in Human Renal Cell Carcinoma Therapy Cancer Research, 66 (10).

Full text not available from this repository.

Abstract

Metastatic renal cell carcinoma is resistant to current therapies. The phosphoinositide 3-kinase (PI3K)/Akt signaling cascade induces cell growth, cell transformation, and neovascularization. We evaluated whether targeting this pathway could be of therapeutic value against human renal cell carcinoma. The activation of the PI3K/Akt pathway and its role in renal cell carcinoma progression was evaluated in vitro in seven human cell lines by Western blot, cell counting, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, terminal deoxyribonucleotide transferase-mediated nick-end labeling assays, and fluorescence-activated cell sorting analysis, using two PI3K inhibitors, LY294002 and wortmannin, as well as by transfection with various Akt constructs and through Akt knockdown by small interfering RNA (siRNA). In vivo nude mice bearing human renal cell carcinoma tumor xenografts were treated with LY294002 (75 mg/kg/wk, 4 weeks, i.p.). Tumor growth was measured and tumors were subjected to Western blot and immunohistochemical analysis. Akt was constitutively activated in all cell lines. Constitutive phosphorylation of glycogen synthase kinase-3 (GSK-3) was observed in all cell lines, whereas forkhead transcription factor and mammalian target of rapamycin, although expressed, were not constitutively phosphorylated. Exposure to LY294002 or wortmannin decreased Akt activation and GSK-3 phosphorylation and reduced cell growth by up to 70% through induction of cell apoptosis. These effects were confirmed by transfection experiments with Akt constructs or Akt siRNA. Importantly, LY294002 induced up to 50% tumor regression in mice through tumor cell apoptosis. Tumor neovascularization was significantly increased by LY294002 treatment. Blood chemistries showed no adverse effects of the treatment. Our results suggest an important role of PI3K/Akt inhibitors as a potentially useful treatment for patients with renal cell carcinoma.

Item Type: Article
Divisions : Faculty of Health and Medical Sciences > School of Biosciences and Medicine > Department of Biochemical Sciences
Authors :
NameEmailORCID
Sourbier, CUNSPECIFIEDUNSPECIFIED
Lindner, VUNSPECIFIEDUNSPECIFIED
Lang, HUNSPECIFIEDUNSPECIFIED
Agouni, Abdelalia.agouni@surrey.ac.ukUNSPECIFIED
Schordan, EUNSPECIFIEDUNSPECIFIED
Danilin, SUNSPECIFIEDUNSPECIFIED
Rothhut, SUNSPECIFIEDUNSPECIFIED
Jacqmin, DUNSPECIFIEDUNSPECIFIED
Helwig, JJUNSPECIFIEDUNSPECIFIED
Massfelder, TUNSPECIFIEDUNSPECIFIED
Date : 16 May 2006
Identification Number : 10.1158/0008-5472.CAN-05-1469
Copyright Disclaimer : © 2006 by the American Association for Cancer Research
Uncontrolled Keywords : Animals, Carcinoma, Renal Cell, Cell Growth Processes, Cell Line, Tumor, Chromones, Enzyme Inhibitors, Humans, Kidney Neoplasms, Male, Mice, Morpholines, Oncogene Protein v-akt, Phosphatidylinositol 3-Kinases, Phosphorylation, RNA, Small Interfering, Signal Transduction, Substrate Specificity, Transfection, Xenograft Model Antitumor Assays
Depositing User : Abdelali Agouni
Date Deposited : 21 Aug 2017 10:41
Last Modified : 21 Aug 2017 10:41
URI: http://epubs.surrey.ac.uk/id/eprint/129072

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800